Cita APA

Isla, D., Lopez-Brea, M., Espinosa, M., Arrabal, N., Pérez-Parente, D., Carcedo, D., & Bernabé-Caro, R. (2023). Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.

Citación estilo Chicago

Isla, Dolores, Marta Lopez-Brea, María Espinosa, Natalia Arrabal, Diego Pérez-Parente, David Carcedo, y Reyes Bernabé-Caro. Cost-effectiveness of Atezolizumab Versus Pembrolizumab As First-line Treatment in PD-L1-positive Advanced Non-small-cell Lung Cancer in Spain. 2023.

Cita MLA

Isla, Dolores, et al. Cost-effectiveness of Atezolizumab Versus Pembrolizumab As First-line Treatment in PD-L1-positive Advanced Non-small-cell Lung Cancer in Spain. 2023.